Evidence map›Paper›PMID 36609595›Full record

ArticleCommunications biology2023

Publisher Correction: A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements.

Robert J Kimmerling, Mark M Stevens, Selim Olcum, Anthony Minnah, Madeleine Vacha, Rachel LaBella, Matthew Ferri, Steven C Wasserman, Juanita Fujii, Zayna Shaheen and 12 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Robert J Kimmerling *Travera, Medford, MA, USA. rkimmerling@travera.com.ORCID http://orcid.org/0000-0002-8920-336X
Mark M Stevens *Travera, Medford, MA, USA.
Selim Olcum *Travera, Medford, MA, USA.
Anthony Minnah *Travera, Medford, MA, USA.
Madeleine Vacha *Travera, Medford, MA, USA.
Rachel LaBella *Travera, Medford, MA, USA.
Matthew FerriTravera, Medford, MA, USA.ORCID http://orcid.org/0000-0003-1265-2834
Steven C WassermanTravera, Medford, MA, USA.
Juanita FujiiDepartment of Clinical Research, Dignity Health, Sequoia Hospital, Redwood City, CA, USA.
Zayna ShaheenDepartment of Clinical Research, Dignity Health, Sequoia Hospital, Redwood City, CA, USA.
Srividya SundaresanDepartment of Clinical Research, Dignity Health, Sequoia Hospital, Redwood City, CA, USA.
Drew RibadeneyraWeill Cornell Medicine, New York, NY, USA.
David S JayabalanWeill Cornell Medicine, New York, NY, USA.
Sarita AgteDepartment of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Adolfo AlemanDepartment of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Joseph A CriscitielloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ruben NiesvizkyWeill Cornell Medicine, New York, NY, USA.
Marlise R LuskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5781-4529
Samir ParekhDepartment of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-9694-8469
Cara A RosenbaumWeill Cornell Medicine, New York, NY, USA.
Anobel TamraziDivision of Vascular and Interventional Radiology, Palo Alto Medical Foundation, Redwood City, CA, USA.
Clifford A ReidTravera, Medford, MA, USA. creid@travera.com.ORCID http://orcid.org/0000-0002-9438-9349
Cornell University · USIcahn School of Medicine at Mount Sinai · USSequoia Hospital · USDana-Farber Cancer Institute · USTraverse Biosciences (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36609595
PMCPMC9823002
OpenAlexW4313641728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.